FindTrial
Sign In

Topical Corticosteroid (TCS)

OTHER3 trials

Sponsors

Regeneron Pharmaceuticals, Eli Lilly and Company

Conditions

Atopic DermatitisEczema

Phase 2

Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
CompletedNCT01639040
Regeneron PharmaceuticalsAtopic Dermatitis
Start: 2012-07-31End: 2012-12-31Updated: 2017-10-13

Phase 3

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
CompletedNCT02260986
Regeneron PharmaceuticalsAtopic Dermatitis
Start: 2014-09-30End: 2016-10-31Updated: 2017-10-17
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Active, not recruitingNCT05559359
Eli Lilly and CompanyAtopic Dermatitis, Eczema
Start: 2022-10-18End: 2026-12-01Updated: 2026-01-21

Related Papers

Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison
SKIN The Journal of Cutaneous Medicine2026-03-10
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.
2026-01-21
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.
2025-11-22
Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis.
2025-10-16
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults
American Journal of Clinical Dermatology2025-09-24
Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.
2025-09-19
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials
Advances in Therapy2025-02-192 citations
Dupilumab Demonstrates a Higher Likelihood of Achieving Improvements in Signs, Symptoms, and Quality of Life vs. Tralokinumab at Week 16: Results from a Bucher Indirect Treatment Comparison
SKIN The Journal of Cutaneous Medicine2024-11-18
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis
Frontiers in Immunology2024-11-116 citations
686 - Impact of dupilumab treatment on seasonal disease severity in adults with moderate-to-severe atopic dermatitis
British Journal of Dermatology2024-08-011 citations
695 - Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis
British Journal of Dermatology2024-08-011 citations
618 - A Bayesian network meta-analysis comparing the efficacy of dupilumab versus tralokinumab in adults with severe atopic dermatitis with inadequate response or intolerance to cyclosporin A
British Journal of Dermatology2024-08-01
675 - Dupilumab demonstrates higher likelihood of achieving improvements in signs, symptoms, and quality of life vs lebrikizumab: results from a placebo-adjusted indirect comparison analysis
British Journal of Dermatology2024-08-01
690 - SCORAD severity band threshold analysis from dupilumab clinical trials in adults with moderate-to-severe atopic dermatitis
British Journal of Dermatology2024-08-01
685 - Onset and maintenance of optimal itch response in adult patients with moderate-to-severe atopic dermatitis treated with dupilumab: post hoc analysis from LIBERTY AD CHRONOS
British Journal of Dermatology2024-08-01
417 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
British Journal of Dermatology2023-06-011 citations
410 Dupilumab treatment reduces total IgE levels in patients 6 months and older with moderate-to-severe atopic dermatitis
British Journal of Dermatology2023-06-01
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
2023-02-2012 citations
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis
JAMA Dermatology2023-02-0116 citations
339 Dupilumab 16-week efficacy and safety are robust and consistent in adults over 60 years of age with moderate-to-severe atopic dermatitis
British Journal of Dermatology2023-01-25

22 more papers not shown